

Supplementary Table 4. Risk prediction models for incident Alzheimer disease in post-kidney transplantation recipients

Variable	Model ^a		Model ^b	
	HR (95% CI)	p-value	HR (95% CI)	p-value
Age grading (yr)				
40–44	0 (0)	>0.99	0 (0)	>0.99
45–49	0.72 (0.12–4.31)	0.72	0.77 (0.13–4.60)	0.77
50–54	1 (Reference)		1 (Reference)	
55–59	6.18 (1.74–21.94)	0.005	5.61 (1.58–19.99)	0.008
60–64	7.66 (2.07–28.32)	0.002	6.63 (1.78–24.74)	0.005
65–69	32.98 (9.46–115.00)	<0.001	30.21 (8.48–10.76)	<0.001
≥70	43.74 (8.73–219.13)	<0.001	32.24 (6.30–165.07)	<0.001
Sex				
Female vs. male	0.94 (0.51–1.73)	0.84	1.24 (0.65–2.37)	0.52
Income				
Medical aid	1 (Reference)		1 (Reference)	
Q1	2.03 (0.49–8.52)	0.33	0.80 (0.19–3.41)	0.76
Q2	3.03 (0.80–11.43)	0.10	0.96 (0.25–3.76)	0.95
Q3	1.33 (0.32–5.58)	0.70	0.43 (0.10–1.85)	0.26
Q4	3.14 (0.94–10.511)	0.06	0.91 (0.26–3.20)	0.89
Diabetes mellitus	3.55 (1.85–6.81)	<0.001	2.06 (1.03–4.11)	0.04
Hypertension	3.63 (0.50–26.35)	0.20	2.08 (0.28–15.43)	0.48
Dyslipidemia	3.22 (1.58–6.55)	0.001	2.04 (0.98–4.27)	0.06
Cardiovascular disease	2.51 (1.37–4.60)	0.003	1.23 (0.69–2.44)	0.42
Dialysis vintage period	1.01 (0.91–1.11)	0.92	1.03 (0.93–1.15)	0.56
Immunosuppressants				
Desensitization	1.86 (0.88–3.92)	0.10	1.84 (0.85–3.99)	0.12
Induction				
ATG	1 (Reference)		1 (Reference)	
Basiliximab	0.71 (0.25–1.99)	0.51	0.84 (0.29–2.44)	0.75
Maintenance CNI				
Tacrolimus	1 (Reference)		1 (Reference)	
Cyclosporine	0.88 (0.41–1.91)	0.75	1.05 (0.48–2.32)	0.91

ATG, antithymocyte globulin; CI, confidence interval; CNI, calcineurin inhibitor; HR, hazard ratio; Q, quartile.

^aUnadjusted. ^bAdjusted for age, sex, diabetes mellitus, hypertension, dyslipidemia, income, cardiovascular disease, dialysis vintage period, and immunosuppressants.